Article
A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2020
Ghosh Chandrayee, Kumar Suresh, Kushchayeva Yevgeniya, Gaskins Kelli, Boufraqech Myriem, Wei Darmood, Gara Sudheer Kumar, Zhang Lisa, Zhang Ya-Qin, Shen Min, Mukherjee Sanjit, Kebebew Electron
Abstract excerpt
PURPOSE: Most aggressive thyroid cancers are commonly associated with a BRAF V600E mutation. Preclinical and clinical data in BRAF V600E cancers suggest that combined BRAF and MEK inhibitor treatment results in a response, but resistance is common. One mechanism of acquired resistance is through persistent activation of tyrosine kinase (TK) signaling by alternate pathways. We hypothesized that combination therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.